- Home
- MUFG vs TMO Comparison
MUFG vs TMO Comparison
Compare MUFG & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | TMO |
|---|---|---|
| Founded | 1880 | 1956 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.1B | 223.0B |
| IPO Year | 2002 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MUFG | TMO |
|---|---|---|
| Price | $22.24 | $628.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $636.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 05-15-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.32% | 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | N/A | ★ 9.10 |
| Revenue | N/A | ★ $20,918,000,000.00 |
| Revenue This Year | $4.62 | $6.55 |
| Revenue Next Year | $10.12 | $5.11 |
| P/E Ratio | ★ $25.47 | $69.09 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $14.65 | $435.27 |
| 52 Week High | $23.25 | $643.99 |
Technical Indicators
Market Signals| Indicator | MUFG | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 71.36 |
| Support Level | $21.81 | $587.15 |
| Resistance Level | $23.11 | $628.08 |
| Average True Range (ATR) | 0.27 | 15.15 |
| MACD | -0.13 | 1.27 |
| Stochastic Oscillator | 38.86 | 71.41 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).